Disclosures for "Safety and tolerability of adjunctive linezolid with high or standard dose rifampin for the treatment of adults with HIV-associated tuberculous meningitis in Uganda: preliminary findings from the ALTER trial")
-
Dr. Kibengo has nothing to disclose.
-
Dr. Kabarambi has nothing to disclose.
-
Mr. Kafeero has nothing to disclose.
-
Dr. Patrick has nothing to disclose.
-
Dr. NAKIMBUGWE has nothing to disclose.
-
Mr. Ssemaganda has nothing to disclose.
-
Mr. Tayebwa has nothing to disclose.
-
The institution of Dr. Nahid has received research support from NIH .
-
The institution of Fiona Cresswell has received research support from Janssen.
-
Dr. Chow has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Medicolegal consulting. The institution of Dr. Chow has received research support from NIH.